Mediphage is developing safe and re-dosable non-viral gene therapies based on its proprietary linear, covalently closed and double-stranded mini-string DNA (msDNA) platform technology. Mediphage’s platform technology is versatile and confers applications in gene addition, in vivo gene editing and ex vivo gene editing for cell therapy approaches, plasmids for recombinant viral vector production and DNA vaccines.

Mediphage Bioceuticals logo



Event details

Date: January 9 - 11, 2023

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences


13 in total